#United States #Wilmington #chromatography #DuPont #AmberChrom

DuPont Unveils Groundbreaking Chromatography Resins

DuPont has recently made waves in the bioprocessing field with the launch of its latest chromatography resins: DuPont™ AmberChrom™ XT20 SL and XT30 SL. These innovations represent a significant advancement in the purification processes used in biopharmaceutical manufacturing, particularly for oligonucleotide and peptide therapies.

Streamlining Biopharmaceutical Workflows

As targeted therapies rise in demand, manufacturers are constantly searching for ways to enhance efficiency without sacrificing quality. The introduction of the AmberChrom™ XT SL resins comes as a much-needed solution to the complexities involved in downstream processing. Traditionally, preparing chromatography resins required extensive steps, including hydration before packing into columns. This procedure not only consumed valuable time but also necessitated additional equipment and financial resources.

DuPont’s new slurried chromatography resins eliminate the hydration requirement, allowing manufacturers to go straight from resin delivery to column packing. By streamlining this process, the AmberChrom resins help reduce preparation time substantially. This change not only expedites the overall process but also lowers operational costs associated with resin preparation.

Key Features of AmberChrom™ XT20 SL and XT30 SL

AmberChrom™ XT20 SL

Designed specifically for applications requiring high-resolution separations, the AmberChrom™ XT20 SL resin is the finest particle-size resin in the AmberChrom portfolio. This makes it ideal for advanced purification tasks where precision is paramount.

AmberChrom™ XT30 SL

On the other hand, the AmberChrom™ XT30 SL resin offers flexibility for optimized separations at higher flow rates. This option is particularly beneficial during various purification and polishing procedures involved in the manufacturing of oligonucleotides and peptides. By providing these two distinct options, DuPont caters to a broader range of manufacturing needs, helping companies adapt as required across different therapeutic developments.

Meeting the Demand for Targeted Medicines

The growing sector of oligonucleotide and peptide therapeutics addresses a multitude of conditions including genetic disorders, metabolic syndromes like diabetes and obesity, and certain forms of cancer. These advanced medicines necessitate the utmost purity and consistency during manufacturing to ensure safety and efficacy in clinical applications. DuPont's AmberChrom™ XT resins provide the quality needed to meet stringent industry standards, supporting manufacturers to maintain reliability in their processes.

Shane Kendra, Global Bioprocessing Market Leader for DuPont Water Solutions, emphasized the importance of this new launch when he stated, "As oligonucleotide and peptide therapies continue to gain momentum, manufacturers are under increasing pressure to improve efficiency without compromising performance. The introduction of DuPont™ AmberChrom™ XT20 SL and XT30 SL resins simplifies downstream processing by removing time-and capital-intensive preparation steps while maintaining the high standards required for biopharmaceutical applications."

Supporting Continuous Production

With the demand for biopharmaceuticals like oligonucleotide and peptide therapies on the rise, maintaining a balance between production efficiency and quality becomes imperative for manufacturers. The AmberChrom™ XT SL resins not only provide a means to streamline operations but also offer high-resolution capabilities essential for complex separations required in modern bioprocessing applications. By facilitating these advancements, DuPont continues on its mission to enhance production efficiencies and ultimately support the evolution of therapies that can improve patient outcomes.

To learn more about the AmberChrom™ XT SL chromatography resins and how they fit into DuPont's comprehensive bioprocessing portfolio, please visit DuPont’s website.

Conclusion

In an ever-evolving medical landscape, innovations such as DuPont’s AmberChrom™ XT20 SL and XT30 SL resins are pivotal for maintaining progress in biopharmaceutical manufacturing. By investing in technologies that simplify complex processes while ensuring quality, DuPont reaffirms its commitment to advancing healthcare solutions and supporting the accessibility of targeted therapies.